Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

153 results about "7-ACA" patented technology

7-ACA (7-aminocephalosporanic acid) is the core chemical structure for the synthesis of cephalosporin antibiotics and intermediates. It can be obtained by chemoenzymatic hydrolysis of cephalosporin C.

Synthesis of antibiotic ceftazidime, ceftazidime for injection and preparation method of ceftazidime

The invention discloses synthesis of antibiotic ceftazidime, ceftazidime for injection and a preparation method of ceftazidime. 7-ACA is served as a raw material, silanization and iodo reaction are carried out, and pyridine, hydrochloric acid and water are added to obtain TA (7-PyCA); ceftazidime active ester is added in an organic solvent and an inorganic solvent to obtain new modified ceftazidime active ester; TA is added in new modified ceftazidime active ester, organic mixed solvent and triethylamine are added, then acid water and an acetone solution are added to obtain TC (ceftazidime dihydrochloride), and ceftazidime is obtained through the reaction. The synthesis of ceftazidime provided by the invention has the advantages that ceftazidime is high in yield, operation processes are simplified, production cost is low, ceftazidime is applicable to industrial production, obtained products can be stored for a long time, a structure is stable, and impurity content is low. Ceftazidime for injection has the advantages of being moderate in grain size, good in clarity, less in impurity content, excellent in quality, stable and the like, and is high in split charging efficiency in production, good in content uniformity, high in medicine dissolution rate in clinical application and good in dissolubility.
Owner:国药集团致君(苏州)制药有限公司 +1

Process for preparing cefathiamidine

The invention relates to the field of the synthesis of chemical medicaments and discloses a preparation method of cefathiamidine; the method takes chloracetyl chloride as a raw material and comprises the following steps: (1) on the condition of the presence of a solvent, alkali is added so as to cause 7-ACA to be dissolved, and then the chloracetyl chloride is added for a condensation reaction; after the condensation reaction is finished, chloracetyl 7-ACA crystals are separated out with an acid; and (2) on the condition of the presence of both the solvent and a catalyst of a catalyzing amount, the chloracetyl 7-ACA reacts with N, N-di-isopropyl thiourea to produce the cefathiamidine. Besides the advantages of bromoacetyl-bromide preparation method of cefathiamidine, the technology of adopting chloracetyl chloride as the raw material to produce the cefathiamidine also has the advantages that: as no alkali is added into the reaction between the chloracetyl 7-ACA and the N, N-di-isopropyl thiourea, the produced cefathiamidine has lighter color, and better and more stable quality, is more beneficial to store and transport, improves the overall yield, lowers the cost and has broader prospects; and the price of the chloracetyl chloride is one sixth of that of the bromoacetyl bromide, which significantly reduce the cost.
Owner:GUANGZHOU BAIYUNSHAN PHARM CO LTD

Comprehensive recovery method for effective ingredients in 7-amidogen cephalosporins alkanes acid crystallization mother liquor produced through enzymatic hydrolysis method

The invention belongs to the technical field of pharmacy, and relates to a comprehensive recovery method for effective ingredients in 7-amidogen cephalosporins alkanes acid crystallization mother liquor produced through an enzymatic hydrolysis method. The method comprises the following steps that 1, the 7-ACA mother liquor is prepared; 2, 7-ACA and CPC are adsorbed and decomposed; 3, D-alpha-aminoadipicacid is prepared; 4, 7-ACA is prepared. 7-ACA and D-alpha-aminoadipicacid in the 7-ACA crystallization mother liquor are separated through the specific adsorption effect of macroreticular resin on 7-ACA, appropriate decomposition agents is adopted for decomposing 7-ACA and CPC adsorbed to the resin, then D-alpha-aminoadipicacid and 7-ACA are recovered from adsorption raffinate and decomposition liquid respectively, the quality of the recovered 7-ACA products is superior to that of 7-ACA products obtained through the enzymatic hydrolysis method, and D-alpha-aminoadipicacid can be used for preparing a fermentation medium of CPC. The effective ingredients in the mother liquor are successfully recovered through the brand-new process, the emission of high-concentration waste water is greatly reduced, the cost for treating sewage is reduced, and environment-friendly, clean and green production is achieved.
Owner:SHANXI WEIQIDA PHARMA IND

Preparation method for cefotaxime acid

The invention discloses a preparation method for cefotaxime acid, and belongs to the technical field of medicine. The preparation method comprises the following steps: firstly mixing dichloromethane with ethanol, purified water and isopropyl alcohol, and then adding 7-ACA (aminocephalosporanic acid), AE-active ester and antioxygen to obtain mixed liquor; dropwise adding triethylamine into the mixed liquor in 2 to 3 hours for a reaction, and when HPLC (high performance liquid chromatography) is adopted to detect that 7-ACA residual amount is less than 1 percent, regarding as a complete reaction; adding sodium bicarbonate aqueous solution of which the mass concentration is 1 percent to 5 percent for extraction, after reduced pressure suction filtration on an aqueous phase, adding acetone and mixing, dropwise adding hydrochloric acid of which the mass concentration is 10 percent to 25 percent under temperature of 10 to 15 DEG C until a pH (potential of hydrogen)value is 2.5 to 3.0, and cultivating crystals for 1 to 3 hours; centrifuging, spin-drying, leaching, and drying after spin-drying to obtain the cefotaxime acid. The cefotaxime acid prepared by the invention has uniform particle size distribution and stable performance; mass yield reaches more than 170 percent, and product purity can reach more than 99 percent.
Owner:HENAN KANGDA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products